THE IMMUNOSUPPRESSIVE ACTIVITIES OF NEWLY SYNTHESIZED AZAPHENOTHIAZINES IN HUMAN AND MOUSE MODELS

MICHAŁ ZIMECKI¹, JOLANTA ARTYM¹, MAJA KOCIEBA¹, KRYSTIAN PLUTA²*, BEATA MORAK-MŁODAWSKA² and MAŁGORZATA JELEN²

¹Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Department of Experimental Therapy, R. Weigla 12, 53-114 Wrocław, Poland, ²The Medical University of Silesia, Department of Organic Chemistry, Jagiellońska 4, 41-200 Sosnowiec, Poland

Abstract: In this study, we evaluated the activities of new types of azaphenothiazines in the following immunological assays: the proliferative response of human peripheral blood mononuclear cells induced by phytohemagglutinin A or anti-CD3 antibodies; lipopolysaccharide-induced cytokine production by human PBMC; the secondary, humoral immune response in mice to sheep erythrocytes (in vitro); and delayed-type hypersensitivity in mice to ovalbumin (in vivo). In some tests, chlorpromazine served as a reference drug. The compounds exhibited differential inhibitory activities in the proliferation tests, with 10H-2,7-diazaphenothiazine (compound 1) and 6-(3-dimethylaminopropyl)diquinothiazine (compound 8) being most suppressive. Compound 1 was selected for further studies, and was found to be...
strongly suppressive in the humoral immune response even at low concentrations (1 µg/ml). Compound 1 also inhibited the delayed-type hypersensitivity lipopolysaccharide-induced production of tumor necrosis factor and interleukin-6 in cultures of human blood cells. As there were only two subjects in this study, the effects of these compounds on human blood cells need to be confirmed. In this paper, we also discuss the structure-activity relationships of selected compounds.

**Key words:** Azaphenothiazines, Immune response, PBMC, Proliferation, Cytokines

**INTRODUCTION**

Phenothiazine-like drugs exhibit significant pharmacological effects, including antipsychotic, antihistamine, antitussive and antiemetic activities, and they possess interesting chemical properties [1]. Recent reports also describe anticancer [2-4], antiplasmid [5] and antibacterial activities [6, 7], and reversal of multidrug resistance (MDR) [8, 9]. Furthermore, there are potential applications for both classical and newly synthesized phenothiazines in the treatment of Alzheimer’s disease [10], Creutzfeldt-Jakob disease [6] and AIDS [11]. Neuroleptic phenothiazines are potent modulators of immune functions. Numerous papers have described the inconsistent effects of phenothiazines, in particular chlorpromazine, on induced cytokine production in human and animal models. However, several articles [12-16] reported that this compound inhibits the release of tumor necrosis factor-alpha (TNF-α), which is induced by various stimuli. Although chlorpromazine was shown to reduce the endotoxin-induced production of interleukin TNF-α in a mouse model, it did not inhibit IL-1 or IL-6 production, and IL-10 production even increased [16]. In cultures of human peripheral blood mononuclear cells (PBMC), chlorpromazine had no effect on endotoxin-induced cytokine production, but some studies showed its suppressive effects on TNF-α, IL-2 and IFN-γ expression or release by human immunocompetent cells [15-18].

New phenothiazines were obtained by modifying the parent phenothiazine structure mainly by introducing a new substituent at the thiazine nitrogen atom at position 10 and by substituting one or two benzene rings with homoaromatic and heteroaromatic rings. In the next step of the search for pharmacocative pyridine and quinoline derivatives, we modified the phenothiazine structure with pyridine and quinoline rings to form new types of heterocyclic compounds: dipyrido-1,4-thiazines (2,7-diazaphenothiazines), and the linear and angular fused diquino-1,4-thiazines (pentacyclic dibenzo-1,9-diazaphenothiazines and dibenzo-3,7-diazaphenothiazines) [19-23]. Some of these azaphenothiazines exhibit promising anticancer activities against human tumor cell lines deriving...
from the colon, breast, kidneys, ovaries, prostate and CNS, and against melanoma and leukemia cell lines [19, 23, Pluta et al.]

To the best of our knowledge, there has been no report on the immunomodulatory action of any azaphenothiazines. In this paper, we describe and discuss the immunomodulatory activities of the recently synthesized azaphenothiazines 1-10 – five 10H- or 10-substituted 2,7-diazaphenothiazines (1-5), and five 6-substituted dibenzo-1,9-diazaphenothiazines (6-10) – in selected immunological assays using human and mouse models. These compounds possess different types of substituents at the thiazine nitrogen atom (hydrogen, alkyl, aryl, dialkiloaminoalkyl, acetylaminoalkyl and sulfonylaminoalkyl). Of note, compound 9 possesses the nitrogen half-mustard unit (the 2-chloroethylamino group), and compound 6 has the ethylene unit forming the additional dihydro-1,3-diazole ring (Fig. 1).

**MATERIALS AND METHODS**

**Reagents**

Sheep red blood cells (SRBC) were provided by the Wroclaw University of Environmental Sciences (Wrocław, Poland). They were kept in Alsever’s solution at 4°C until needed. MTT, RPMI-1640 medium, DMSO (dimethyl sulfoxide), LPS (lipopolysaccharide; E. coli serotype O111:B4; 3×10^6 E.U./mg), PHA (phytohemagglutinin), ovalbumin (OVA) and chlorpromazine (2-chloro-10-(3-dimethylaminopropyl)phenothiazine) hydrochloride were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Fetal calf serum (FCS) was supplied by Gibco (Paisley, UK). The complete and incomplete Freund’s adjuvants were from Difco Laboratories (Detroit, Michigan, USA). Lymphoprep was from Pasching (Austria) and anti-CD3 antibodies were from R&D (Minneapolis, USA). All the tissue culture plates and flasks were purchased from Nunc (Denmark).

1 Pluta, K., Morak-Młodawska, B. and Jelen, M. National Cancer Institute Developmental Therapeutics Program, In-Vitro Testing Results, Bethesda, USA (unpublished data)
Mice
CBA mice of both sexes, 1-12 weeks old, were purchased from the Ilkowice Breeding Facility, Poland. The mice were fed a commercial pelleted food and filtered tap water ad libitum. The local ethics committee approved the study.

Blood donors
Blood from a non-smoking 36-year old woman and a non-smoking 60-year old man was used for the study. Written consent was obtained from both donors.

Syntheses
Azaphenothiazines 1-10 were obtained according to recently described procedures. 10H-2,7-diazaphenothiazine 1 was obtained from 3-amino-3’-nitro-4,4’-dipyridinyl sulfide in DMF [19]. Compounds 2-4 (10-methyl-, 10-(p-nitrophenyl)- and 10-(3-dimethylamino-2-methylpropyl)-2,7-diazaphenothiazine) were obtained from compound 1 by N-alkylation and N-arylation with methyl iodide and with 4-fluoronitrobenzene in DMF in the presence of sodium hydride, and with 3-dimethylamino-2-methylpropyl chloride in dioxane in the presence of sodium hydroxide [19]. Compound 5 (10-(3-acetylaminopropyl)-2,7-diazaphenothiazine) was obtained by N-alkylation of compound 1 with N-(3-bromopropyl) phthalimide in toluene in the presence of sodium hydride followed by hydrolysis with hydrazine and acetylation with acetic anhydride [24]. Compound 6 (5,6-ethylenediqinothiazinium chloride) was synthesized in the annulation reaction of 2,2’-dichloro-3,3’-diquinolinyl sulfide with 2-chloroethylamine in a methyl ether of diethylene glycol in an autoclave [22]. Compounds 7 and 8 (6-(2-diethylamino)ethylqinothiazine and 6-(3-dimethylaminopropyl)diquinothiazine) were synthesized from 6H-diquinothiazine in a reaction with 2-diethyaminoethyl and 3-dimethylaminopropyl chlorides in dioxane in the presence of sodium hydroxide. Compounds 9 and 10 (6-(2-chloroethylureido)ethylqinothiazine and 6-(2-p-toluene sulfonyl)ethylqinothiazine) were synthesized from 2,2’-dichloro-3,3’-diquinolinyl chloride in a reaction of 1,2-diaminoethane followed by a reaction with 2-chloroethyl isocyanate and p-toluene sulfonyl chloride [23].

The proliferation test
The venous blood from the two healthy donors was taken into heparinized tubes and diluted twice with phosphate buffered saline (PBS), applied onto Lymphoprep (density 1.077 g/ml) and centrifuged for 20 min at 800×g. The cells from the interphase were collected, washed twice with Hanks’ medium and resuspended in a culture medium consisting of RPMI-1640 supplemented with L-glutamine, sodium pyruvate, 2-mercaptoethanol and 10% FCS (referred to hereafter as the culture medium). The cells were distributed into 96-well flat-bottom plates (2×10⁵/100 µl/well). PHA was added at a dose of 5 µg/ml, and the studied compounds were added at a concentration of 1, 10 and 100 µg/ml. The cells were cultured for 3 days in a cell culture incubator. After the incubation, the proliferation rate was measured using a colorimetric MTT method [25].
The results were presented as the mean optical density values from quadruplicate wells.

The toxicity test
Mouse splenocytes (pooled from three mice) were distributed in the culture medium into 96-well flat-bottom plates at a concentration of 2×10^5/100 µl/well. The studied compounds were added at a final concentration range of 50.0-1.56 µg/ml. After overnight incubation, the cells were treated with 0.25 µl of MTT [25], and the cell viability was measured as the optical density at 550/630 nm. The results were presented as the mean optical density values from quadruplicate wells.

The secondary, humoral immune response to sheep erythrocytes in vitro
Mice were sensitized intraperitoneally (i.p.) with 0.2 ml of a 5% sheep red blood cell (SRBC) suspension. After 4 days, the spleens from 5 mice were isolated, and a single cell suspension was prepared in the culture medium. The cells were distributed into 24-well plates at 5×10^6 cells/ml/well, and 0.1 ml of 0.005% SRBC was added. The studied compound was added at a concentration of 1 and 10 µg/ml at the beginning of a 4-day culture in a cell culture incubator. The number of antibody-forming cells (AFC) was determined by a method of local hemolysis in agar gel [26]. The results were presented as mean AFC numbers from 4 wells per 10^6 splenocytes.

Delayed hypersensitivity to ovalbumin
Mice were sensitized subcutaneously (s.c.) in the tail base with 5 µg of ovalbumin (OVA) emulsified in complete Freund’s adjuvant. After 4 days, the delayed-type hypersensitivity (DTH) reaction was elicited by a s.c. injection of 50 µg OVA emulsified in incomplete Freund’s adjuvant into the hind foot pads. The studied compound was administered i.p. 1 h before the sensitizing dose of antigen. The control mice were non-sensitized animals given only the eliciting dose of the antigen. The foot pad edema was measured using a caliper 24 h after the s.c. injection. The antigen-specific foot pad edema was calculated by subtracting the background control response, and the results were expressed in DTH units [27].

Induction of cytokines in peritoneal exudate cell cultures
Peritoneal exudate cells were obtained from mice by washing the peritoneal cavities with 5 ml of Hanks’ medium containing 5 units of heparin. After the wash in Hanks’ medium, the cells were re-suspended in the culture medium and placed at a density of 10^6/ml/well in 24-well culture plates. The cells were stimulated with 5 µg/ml of E. coli LPS for 24 h in a cell culture incubator. The compound was added at 1, 10 and 100 µg/ml concentrations with DMSO at the appropriate dilutions. The activities of TNF-α and IL-6 were respectively determined in the supernatants via bioassays using WEHI 164.13 [28] and 7TD1 cell lines [29].
Induction of cytokines in human blood cell cultures
Venous blood was diluted 5× with RPMI-1640 (0.5×10⁶ cells/ml). The cell suspension was placed in 24-well culture plates (1 ml/well) and stimulated with 1 µg/ml of LPS. The compound was used at concentrations of 0.1, 1 and 10 µg/ml. After a 24-h culture, the activities of TNF-α and IL-6 were measured in the supernatants using bioassays [28, 29].

Statistics
The differences across groups were determined by analysis of variance after testing the homogeneity of variance using Levene’s test. Individual grades were then compared using Tukey’s test for multiple comparisons. The data is expressed as means ± SE (standard error). The effects of the compounds were compared with the appropriate dilutions of DMSO (the solvent). Differences were considered significant when P was less than 0.05. The statistical analysis was performed using STATISTICA 6.0 for Windows.

RESULTS
The effects of the compounds on phytohemagglutinin A and anti-CD3 antibody-induced proliferation of human peripheral blood mononuclear cells
The effects of the compounds on the proliferative response of human PBMC to PHA (assessed on one representative blood donor) are shown in Figs 2 and 3. Chlorpromazine served as a reference drug. Compounds 6-10 (Fig. 3) were distinctly inhibitory at concentrations as low as 10 µg/ml, and compounds 6 and 8 even exhibited strong activity at 1 µg/ml. Compounds 9 and 10 were much less active, although compound 9 did show a strong suppressive activity at 100 µg/ml. Compounds 1 and 2 were distinctly inhibitory at 10 µg/ml, but 3-5 showed a little activity (Fig. 2). Compound 1 was exceptionally suppressive at 100 µg/ml. We also tested the effects of compounds 1 and 8, at 10 and 100 µg/ml concentrations, on the proliferative response of human PBMC stimulated with anti-CD3 antibodies in parallel with stimulation with PHA (Fig. 4). It appeared that cell proliferation was blocked by both concentrations of compound 8 and chlorpromazine, but by compound 1 only at 100 µg/ml.

Toxicity of the compounds
Since the inhibitory effects of the compounds could have been caused by high cytotoxicity, the compounds were tested for their effects on mouse splenocyte viability in an overnight culture. The compounds were used at a wide concentration range (50 µg/ml-1.56 µg/ml). The reference compound was chlorpromazine. The results, presented in Fig. 5A and B, revealed that at the concentrations tested, compounds 1-5 were virtually devoid of toxicity, whereas some of compounds 6-10 appeared to be toxic (6, 7 and particularly 8, which exhibited high toxicity even at their lowest concentrations). High toxicity was found with chlorpromazine (50 µg/ml-12.5 µg/ml).
Fig. 2. The effects of compounds 1-5 on the proliferative response of human mononuclear blood cells to phytohemagglutinin A. The compounds were added to PHA-stimulated PBMC cultures at concentrations of 1, 10 and 100 µg/ml. After a 3-day incubation, the rate of cell proliferation was determined using the MTT colorimetric method. (-) – no additions. Statistics: 1 µg/ml: all comparisons NS; 10 µg/ml: DMSO vs Chlorpromazine, P = 0.0001; DMSO vs Compound 1, P = 0.0001; DMSO vs Compound 2, P = 0.0001; 100 µg/ml: DMSO vs Chlorpromazine, P = 0.0001; DMSO vs Compound 1, P = 0.0001; DMSO vs Compound 2, P = 0.0001; DMSO vs Compound 3, P = 0.0001; DMSO vs Compound 4, P = 0.0021; DMSO vs Compound 5, P = 0.0001 (ANOVA).

Fig. 3. The effects of compounds 6-10 on the proliferative response of human mononuclear blood cells to phytohemagglutinin A. The experiment was performed as described under Fig. 2. The compounds were used at concentrations of 1, 10 and 100 µg/ml. (-) – no additions. Statistics: 1 µg/ml: DMSO vs Compound 6, P = 0.0025; DMSO vs Compound 8, P = 0.0001; 10 µg/ml: DMSO vs Chlorpromazine, P = 0.0001; DMSO vs Compound 6, P = 0.0001; DMSO vs Compound 7, P = 0.0001; DMSO vs Compound 8, P = 0.0001; 100 µg/ml: DMSO vs Chlorpromazine, P = 0.0001; DMSO vs Compound 6, P = 0.0001; DMSO vs Compound 7, P = 0.0001; DMSO vs Compound 8, P = 0.0001; DMSO vs Compound 9, P = 0.0001; DMSO vs Compound 10, P = 0.0001 (ANOVA).
Fig. 4. The effects of compounds 1 and 8 on the proliferative response of human mononuclear blood cells to PHA and anti-CD3 antibodies. The compounds were added to the cultures at concentrations of 10 and 100 µg/ml. Statistics: CD3 – Control (-) vs CD3, P = 0.0047; DMSO (10-100) vs Chlorpromazine (10-100), P = 0.0002; DMSO (10) vs Compound 8 (10), P = 0.0002; DMSO (100) vs Compound 1 (100), P = 0.0002; DMSO (100) vs Compound 8 (100), P = 0.0002; PHA – Control (-) vs PHA, P = 0.0002; DMSO (10-100) vs Chlorpromazine (10-100), P = 0.0002; DMSO (10) vs Compound 8 (10), P = 0.0002; DMSO (100) vs Compound 1 (100), P = 0.0002; DMSO (100) vs Compound 8 (100), P = 0.0002 (ANOVA).

The effect of compound 1 on the secondary humoral immune response of mouse splenocytes to SRBC in vitro
Because of its low toxicity and high suppressive activity, compound 1 was selected to evaluate effects on the immune response. Fig. 6 demonstrates that the compound is very strongly suppressive with regard to the secondary humoral immune response in vitro, measured as the number of antibody-forming cells to SRBC. The actions of both concentrations (1 and 10 µg/ml were comparable (72.3 and 82.6% suppression, respectively).

The effect of compound 1 on the delayed-type hypersensitivity to OVA in vivo in mice
Compound 1 was also tested for its potential ability to suppress the induction phase of the delayed type hypersensitivity to ovalbumin in vivo. The compound, given before the sensitizing dose of the antigen, inhibited the DTH response in a dose-dependent manner (both inhibitory effects were statistically significant; Fig. 7).
Fig. 5. The effects of compounds 1-5 (A) and 6-10 (B) on the survival of mouse splenocytes. The compounds were incubated overnight at 50-1.56 µg/ml concentrations with mouse splenocytes. The cell viability was measured using the MTT colorimetric method. (-) – no additions. Statistics: A – DMSO (50-6.25) vs chlorpromazine (50-6.25), \( P = 0.0000 \); DMSO (50) vs compound 1 (50), \( P = 0.0108 \) (ANOVA); B – DMSO (50-6.25) vs chlorpromazine (50-6.25), \( P = 0.0000 \); DMSO (50-1.56) vs compound 6 (50-1.56), \( P = 0.0000 \); DMSO (50-1.56) vs compound 7 (50-1.56), \( P = 0.0000 \); DMSO (50-1.56) vs Compound 8 (50-1.56), \( P = 0.0000 \); DMSO (50) vs compound 9 (50), \( P = 0.0000 \) (ANOVA).

Fig. 6. The effect of compound 1 on the secondary humoral immune response of mouse splenocytes to sheep red blood cells. The compound was added to the splenocyte cultures at 1 and 10 µg/ml. The number of antibody-forming cells was determined after four days. (-) – no additions. Statistics: DMSO (1) vs compound 1 (1), \( P = 0.0001 \); DMSO (10) vs compound 1 (10), \( P = 0.0001 \) (ANOVA).
Fig. 7. The effect of compound 1 on the delayed-type hypersensitivity to ovalbumin \textit{in vivo} in mice. The compound was administered to mice at doses of 10 and 100 µg/mouse (p.o.) 1 h before sensitization with OVA. Four days later, the eliciting dose of OVA was administered and 24 h later the DTH reaction was measured. Statistics: DMSO vs compound 1 (10), \( P = 0.0055 \); DMSO vs compound 1 (100), \( P = 0.0001 \) (ANOVA).

Fig. 8. The effect of compound 1 on the lipopolysaccharide-induced production of tumor necrosis factor-alpha (A) and interleukin-6 (B) in human whole blood cell cultures. Compound 1 and chlorpromazine were added to the human whole blood cultures at concentrations of 0.1, 1 and 10 µg/ml. (-) – no additions. After 24 h incubation, the activities of TNF-α and IL-6 were measured in the supernatants using bioassays.
The effect of compound 1 on LPS-induced cytokine production

In cultures of mouse peritoneal exudate cells (data not shown), compound 1 totally inhibited IL-6 production at 100 µg/ml and moderately inhibited TNF-α production at 10 and 100 µg/ml (34 and 25%, respectively). As shown in Fig. 8, compound 1, at a concentration of 10 µg/ml, exhibited a distinct (64%) inhibition of TNF-α production in a culture of whole blood human cells. The compound also inhibited IL-6 production in a dose-dependent manner (17, 27 and 49% inhibition for 0.1, 1 and 10 µg/ml concentration, respectively). Chlorpromazine had no effect in that range of concentration.

DISCUSSION

The newly synthesized compounds 1-10 represent two classes of azaphenothiazines – dipyridothiazines (1-5) and diquinothiazines (6-10) – and show significant anticancer activity against human cancer cell lines. The most active dipyridothiazine was unsubstituted compound 1, with GI50 = 1.70 µg/ml for lung cancer cell line HOP-92. All the diquinothiazines (6-10) turned out to be very active (for example, compound 6: GI50 = 1.30 µg/ml against colon cancer cell line COLO205; compound 7: GI50 = 0.08 µg/ml against ovarian cancer cell line IGROV-1; compound 8: GI50 = 0.11 µg/ml against ovarian cancer cell line IGROV-1; compound 9: GI50 = 0.04 µg/ml against melanoma line SK-MEL-5; compound 10: GI50 = 0.24 µg/ml against renal cancer cell line 786-0. Some other cancer lines were similarly sensitive to those compounds [Pluta et al.]1.

It was interesting to study how the incorporation of two nitrogen atoms into the phenothiazine system in the dipyridothiazines (1-5) and diquinothiazines (6-10), and the addition of two benzene rings in the latter set of compounds influenced their immunological activities, as compared with the activity of a model phenothiazine, chlorpromazine. The results regarding the antiproliferative activities of the studied compounds suggest that the inhibitory activities of compounds 6-10 and the reference drug chlorpromazine could be associated with their toxicity, although the toxicity and proliferation tests were performed on different species. Whereas the toxicity of compounds 6-10 could be attributed to their pentacyclic and hexacyclic ring systems, and to the nitrogen half-mustard unit (in the case of compound 9), the toxicity of tricyclic chlorpromazine may be rather related to its chlorine atom. On the other hand, the tricyclic compounds 1-5 (with two additional nitrogen atoms incorporated in the phenothiazine system) were virtually devoid of toxicity in the concentration range tested. Despite this, two of those compounds (1 and 2, possessing small substituents, i.e. hydrogen and the methyl group) significantly inhibited the proliferative response of PBMC. This inhibition could not be due to the binding of the mitogen (PHA) as shown for other phenothiazines [30], since anti-CD3-induced cell proliferation was also inhibited. It is, however, a likely explanation that the inhibition of both humoral and cellular immune responses by compound
(Figs 6 and 7) was due to the suppression of antigen-specific proliferation of T cells in that model, assuming that the antiproliferative activity of the compound is comparable both for human and mouse lymphocytes. That suppressive effect could be associated with its ability to inhibit the activities of TNF-α and IL-6 (Fig. 8A, B), the cytokines essential in generation of the immune response [31, 32]. Such an effect was not observed with 10 µg/ml of chlorpromazine (Fig. 8A, B). It is also important to stress that unlike the reference drug, chlorpromazine [33], the inhibitory activity of compound 1 could not be related to toxicity, since at the studied concentrations, compound 1 was not toxic for splenocytes (Fig. 5). It seems therefore likely that the suppressive effects of chlorpromazine on PHA-induced PMBC proliferation may be associated with the toxicity of that drug ([34] and Figs 2 and 3).

When discussing the results obtained with human peripheral cells, we should bear in mind that only two blood donors were tested, and given the high variability of immune responsiveness between individuals, the effects of the compounds should be confirmed in a study with more blood donors. We demonstrated that that compound 1 was inhibitory in the immunological assays in vivo and in vitro, and that it likely that its immunosuppressive activity may be associated with the ability to suppress cytokines essential in the initiation of the immune response.

REFERENCES

1. Gupta, R.R. and Kumar, M. Synthesis, properties and reactions of phenothiazines. in: Phenothiazines and 1,4-Benzothiazines – Chemical and Biological Aspects (Gupta, R.R., Ed) Elsevier, Amsterdam, 1988, 1-161.

2. Motohashi, N., Kurihara, T., Sakagami, H., Szabo, D., Csuri, K. and Molnár, J. Chemical structure and tumor type specificity of “half-mustard type” phenothiazines. Anticancer Res. 19 (1999) 1859-1864.

3. Motohashi, N., Kawase, M., Saito, S. and Sakagami, H. Antitumor potential and possible targets of phenothiazine-related compounds. Curr. Drug Targets 1 (2000) 237-245.

4. Motohashi, N., Kawase, M., Saitoh, K. and Sakagami, H. Cytotoxic potential of phenothiazines. Curr. Drug Targets 7 (2006) 1055-1066.

5. [5] Molnár, A., Amaral, L. and Molnár, J. Antiplasmid effect of promethazine in mixed bacterial cultures. Int. J. Antimicrob. Agents 22 (2003) 217-222.

6. Amaral, L. and Kristiansen, J.E. Phenothiazines: potential management of Creutzfeldt-Jacob disease and its variants. Int. J. Antimicrob. Agents 18 (2001) 411-417.

7. Motohashi, N., Kawase, M., Saito, M., Kurihara, T., Saitoh, K., Nakashima, H., Premanathan, M., Arakaki, R., Sakagami, H. and Molnár, J. Synthesis and biological activity of N-acylphenothia-zines. Int. J. Antimicrob. Agents 14 (2000) 203-207.
8. Amaral, L., Martins, M. and Viveiros, M. Enhanced killing of intracellular multidrug-resistant *Mycobacterium tuberculosis* by compounds that affect the activity of efflux pumps. *J. Antimicrob. Chemother.* **59** (2007) 1237-1246.

9. Mayur, Y.C., Jagadeesh, S. and Thimmaiah, K.N. Targeting calmodulin in reversing multi drug resistance in cancer cells. *Mini-Rev. Med. Chem.* **6** (2006) 1383-1389.

10. Mosnaim, A.D., Ranade, V.V., Wolf, M.E., Puente, J. and Valenzuela, M.A. Phenothiazine molecule provides the basic chemical structure for various classes of pharmacotherapeutic agents. *Am. J. Therapeutics* **13** (2006) 261-273.

11. Viveiros, M., Martins, M., Couto, I., Kristiansen, J.E., Molnár, J. and Amaral, L. The *in vitro* activity of phenothiazines against *Mycobacterium avium*: potential of thioridazine for therapy of the co-infected AIDS patients. *In Vivo* **19** (2005) 733-736.

12. Ghezzi, P., Garattini, S., Mennini, T., Bertini, R., Delgado Hernandez, R., Benigni, F., Sacco, S., Skorupska, M., Mengozzi, M., Latini, R., Kurosaki, M., Lombet, A., Fradin, A., Bonnet, J., Rolland, Y. and Brion, J.D. Mechanism of inhibition of tumor necrosis factor production by chlorpromazine and its derivatives. *Eur. J. Pharmacol.* **317** (1996) 369-376.

13. Zinetti, M., Galli, G., Demtri, M.T., Demtri, M.T., Fantuzzi, G., Minto, M., Ghezzi, P., Alzani, R., Cozzi, E. and Fratelli, M. Chlorpromazine inhibits tumor necrosis factor synthesis and cytotoxicity in vitro. *Immunology* **86** (1995) 416-421.

14. Molnár, J., Mandi, Y., Regely, K., Tarnoky, K. and Nakamura, M.J. Inhibition of biological effects of endotoxin by phenothiazines. *In Vivo* **6** (1992) 205-209.

15. Molnár, J., Mándi, Y., Földes, J., Földeák, S., Molnár, M. and Motohashi, N. Effect of phenothiazines, benzo[a]phenothiazines, benz[e]acridines and pentaglobin on endotoxin. *In Vivo* **2** (1995) 463-468.

16. Mengozzi, M., Fantuzzi, G., Faggioni, R., Marchant, A., Goldman, M., Orencole, S., Clark, B.D., Sironi, M., Benigni, F. and Ghezzi, P. Chlorpromazine specifically inhibits peripheral and brain TNF production, and up-regulates IL-10 production, in mice. *Immunology* **82** (1994) 207-210.

17. Pollmächer, T., Haack, M., Schuld, A. Kraus, T. and Hinze-Selch, D. Effects of antipsychotic drugs on cytokine networks. *J. Psych. Res.* **34** (2000) 369-382.

18. Drzyzga, Ł., Obuchowicz, E., Marcinkowska, A. and Herman, Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. *Brain Behav. Immun.* **20** (2006) 532-545.

19. Morak-Mlodawska, B. and Pluta, K. Synthesis of novel dipyrido-1,4-thiazines. *Heterocycles* **71** (2007) 1347-1361.

20. Pluta, K. Synthesis and properties of 14-substituted 1,4-thiazinodiquinolines. *Phosphorus, Sulfur, Silicon* **59** (1997) 145-156.
21. Pluta, K., Maślankiewicz, A. and Szmielew, M. N,N-dialkylaminoalkyl substituted quinobenzo[1,4]thiazines and diquinob[1,4]thiazines. *Phosphorus, Sulfur, Silicon* 159 (2000) 79-86.
22. Nowak, M., Pluta, K., Suwińska, K. and Straver, L. Synthesis of new pentacyclic diquinothiazines. *J. Heterocycl. Chem.* 44 (2007) 543-550.
23. Jeleń, M. and Pluta, K. Synthesis of 6-aminoalkyldiquinithiazines and their acyl and sulfonyle derivatives. *Heterocycles* 75 (2008) 859-870.
24. Morak-Młodawska, B. and Pluta, K. Acyl and sulfonyle derivatives of 10-aminoalkyl-2,7-diazaphenothiazines. *Heterocycles* 78 (2009) in press.
25. Hansen, M.B., Nielsen, S.E. and Berg, K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. *J. Immunol. Methods* 119 (1989) 203-210.
26. Mishell, R.I. and Dutton, R.W. Immunization of dissociated spleen cell cultures from normal mice. *J. Exp. Med.* 126 (1967) 423-442.
27. Lagrange, P.H., Mackaness, G.B., Miller, T.E. and Pardon, P. Influence of dose and route of antigen injection on the immunological induction of T cells. *J. Exp. Med.* 139 (1974) 528-542.
28. Espevik, T. and Nissen-Meyer, J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. *J. Immunol. Methods* 95 (1986) 99-105.
29. Van Snick, J., Cayphas, S., Vink, A., Uyttenhove, C., Coulie, P. G., Rubira, M. R. and R. J. Simpson, R.J. Purification and NH$_2$-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. *Proc. Natl. Acad. Sci. USA* 83 (1986) 9679-9683.
30. Molnar, J., Mandi, Y., Petri, I., Petofi, S., Sakagami, H., Kurihara, T. and Motohashi, N. Immunomodulation activity of phenothiazines, benzo[α]phenothiazines and benzo[c]acridines. *Anticancer Res.* 13 (1993) 439-442.
31. Pasparakis, M., Alexopoulou, L., Episkopou, V. and Kollias, G. Immune and inflammatory responses in TNF-α-deficient mice: a critical requirement for TNF-α in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. *J. Exp. Med.* 184 (1996) 1397-1411.
32. Ceuppens, J.L., Baroja, M.L., Lovre, K., Van Damme, J. and Billiau, A. Human T cell activation with phytohemaglutinin. The function of IL-6 as an accessory signal. *J. Immunol.* 14 (1998) 3868-3874.
33. Waterfield, J.D., Hammarstrom, L. and Smith, E. The effect of membrane stabilizing agents on induction of the immune response. I. Effect of lymphocyte activation in mixed lymphocyte reactions. *J. Exp. Med.* 144 (1976) 562-567.
34. Martinez, F. and Coleman, J.W. The effects of selected drugs, including chlorpromazine and non-steroidal anti-inflammatory agents, on polyclonal IgG synthesis and interleukin 1 production by human peripheral blood mononuclear cells in vitro. *Clin. Exp. Immunol.* 76 (1989) 252-257.